there will be a need for the ii-key peptide-based vaccine...if it works. it will be cheaper, quicker to produce and easier to manage in larger volume than the others. but if it doesn't work it will be worth spit. If that happens we go back to original plan with excellagen leading the way, which in itself wasn't shabby.